SOMA-1

About Coherence Neuro

Coherence Neuro is a private, clinical-stage biotech founded in 2022, operating at the convergence of neurotechnology, neurobiology, and AI to treat cancer. The company's mission is to improve the length and quality of life for cancer patients by introducing a 'fourth pillar' of cancer therapy—bioelectronic modulation—alongside drugs, radiation, and surgery. Their lead program, SOMA, targets high-grade gliomas and has initiated its first safety study, with pipeline expansion into pancreatic cancer underway. Backed by a team of experts from Cambridge, Philips, Siemens, and Abbott, Coherence is building a platform with potential applications across numerous diseases influenced by the body's bioelectric code.

Therapeutic Areas